BOSTON, April 27, 2004 (PRIMEZONE) -- NeuroSystems, LLC announced today that it will exhibit its intelligent multimodality neurosurgical critical care monitoring system at the annual meeting of the American Association of Neurological Surgeons (AANS), May 3-5 in Orlando.
The company's first product, NeuroSystems 1(tm), has been designed to enable and accelerate what the company views as two parallel and interdependent trends: the incorporation of multiple parameters into the regime of neurotrauma and cerebrovascular disease critical care monitoring, and the consolidation of an assortment of individual stand-alone monitors into one comprehensive, intelligent bedside display.
Basic intracranial pressure (ICP) monitoring, though presently the standard of care, is a rather late stage indicator of a patient's status and probable clinical outcome. New sensor technologies which permit the monitoring of other important physical and chemical quantities, including cerebral blood flow (CBF), tissue oxygen and carbon dioxide, pH and brain temperature, have the potential to improve management and outcomes. However, their acceptance has been impeded both by a lack of consensus regarding the clinical significance of any one parameter, and by an inability to monitor the relationships between and among multiple parameters.
"The key to advancing multimodality neuro monitoring is clinical utility," said Dr. James Petite, NeuroSystems' Vice President of Clinical Affairs, "and the key to clinical utility is the ability to display clinically useful higher order relationships between individual data. For example, monitoring cerebral autoregulation is more useful than just looking at separate measurements of cerebral blood flow and arterial pressure. Data in isolation is not enough."
By intelligently blending various individual parameters, NeuroSystems 1 will provide neurosurgeons and other clinicians the ability to monitor higher order, clinically useful neurophysiologic functions including cerebral autoregulation, vasoreactivity and oxygen metabolism, continuously and in real-time, via a series of full-featured clinician displays.
"We are very excited about enabling a long-overdue multimodality revolution in neurosurgical critical care monitoring, and we are moving rapidly toward market introduction," commented Rick Cataldo, NeuroSystems' President. "The AANS is our first exhibit at a major meeting, and a very important milestone for the company."
NeuroSystems' mission is to develop and market intelligent NeuroMonitoring systems which maximize the clinical value of basic monitored parameters through real-time calculation, storage and display of clinically relevant derived parameters and neurophysiologic indicators.